

Ching-Yao Yang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9539962/publications.pdf>

Version: 2024-02-01

12
papers

753
citations

1040018

9
h-index

1199563

12
g-index

12
all docs

12
docs citations

12
times ranked

1512
citing authors

#	ARTICLE	IF	CITATIONS
1	Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes. <i>European Journal of Cancer</i> , 2014, 50, 1361-1369.	2.8	276
2	Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma. <i>European Journal of Cancer</i> , 2016, 57, 91-103.	2.8	120
3	High co-expression of PD-L1 and HIF-1 α correlates with tumour necrosis in pulmonary pleomorphic carcinoma. <i>European Journal of Cancer</i> , 2016, 60, 125-135.	2.8	91
4	PD-L1 is highly expressed in lung lymphoepithelioma-like carcinoma: A potential rationale for immunotherapy. <i>Lung Cancer</i> , 2015, 88, 254-259.	2.0	78
5	Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors. <i>European Journal of Cancer</i> , 2020, 124, 110-122.	2.8	56
6	High PD-L1 expression is associated with stage IV disease and poorer overall survival in 186 cases of small cell lung cancers. <i>Oncotarget</i> , 2017, 8, 18021-18030.	1.8	46
7	Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in Taiwan. <i>Journal of Cancer</i> , 2018, 9, 1813-1820.	2.5	41
8	Outcomes of cancer therapy administered to treatment-naïve lung cancer patients in the intensive care unit. <i>Journal of Cancer</i> , 2017, 8, 1995-2003.	2.5	19
9	Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib. <i>Oncologist</i> , 2020, 25, 702-711.	3.7	17
10	Tyrosine Kinase Inhibitors Improved Survival of Critically Ill EGFR-Mutant Lung Cancer Patients Undergoing Mechanical Ventilation. <i>Biomedicines</i> , 2021, 9, 1416.	3.2	5
11	Globo H expression is associated with driver mutations and PD-L1 expressions in stage I non-small cell lung cancer. <i>Cancer Biomarkers</i> , 2017, 21, 211-220.	1.7	2
12	Successful Management of a ROS1-Rearranged Pulmonary Pleomorphic Carcinoma Using Serial Tyrosine Kinase Inhibitors. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 10123-10127.	2.0	2